



Clinical Effectiveness and Comparative Effectiveness

Gurvaneet Randhawa, MD, MPH
Center for Outcomes and Evidence
Senior Advisor on Clinical Genomics
and Personalized Medicine

SACGHS: June, 2009



“ In theory, theory is just like practice.
In practice, it ain’t.”


– Yogi Berra

Lost in (Research) Translation

Three major hurdles:

- Pre-clinical to clinical efficacy
- Clinical efficacy to effectiveness
- Effectiveness to implementation & use

Integrating Genomics into Practice



Efficacy vs. Effectiveness

- Observed benefits and harms of an intervention in clinical practice differs from expected (from efficacy studies)

- Why?



Patient Factors Influencing Effectiveness of Therapies

- Biology
 - Age
 - Sex
 - Co-morbidities
 - Disease severity
 - Genetic variations
- Other: adherence, cost, preferences, drug-drug interactions

Other Factors Influencing Effectiveness

- Natural history of disease
 - surrogate vs. health outcomes
- Provider: training/skills, experience (e.g. volume of procedures), preferences, time, coverage, liability
- Hospital: volume, availability of devices/tests/therapies, specialty care (e.g. anticoagulation clinics)

Distinguishing Effectiveness from Efficacy Trials

- Primary care population
- Stringency of inclusion/exclusion criteria
- Health outcomes
- Length of study
- Assessment of adverse events
- Adequate sample size
- Intention to treat analysis

Trade-offs

- Efficacy trials: high internal validity, poor applicability, small sample, fast, less cost

- Effectiveness trials: high applicability, large sample, slow, expensive

Example: Warfarin

- Reduces thromboembolic events
- Commonly prescribed
- Narrow therapeutic index: excessive anti-coagulation can lead to bleeding
- Challenges: INR monitoring, drug-drug and diet-drug interactions, adherence

INR Monitoring

- Target range: week – 85%, month – 50%
- Self-monitoring may be useful
- Meta-analysis of 14 RCTs on self-monitoring (\pm self-adjusting dose) shows:

SM: ↑ mean INR in target range (6/11-signf.)

SM: ↓ thromboembolic events (OR=0.45)

SM: ↓ major hemorrhage (OR=0.65)

SM: ↓ mortality (OR=0.61)

Example: Osteoporosis

- Poor adherence to therapy: calcium, vit. D, bisphosphonates, calcitonin, HRT etc.
- Calcium adherence = lower fracture risk
- Alendronate, risedronate, HRT, calcitonin adherence decreases fracture risk
- Weekly users of bisphosphonates had better adherence than daily users

From Outcomes to Decisions

- Efficacy: outcomes in ideal setting
- Effectiveness: outcomes in real-world
- Comparative efficacy (head-head trials)
- Comparative effectiveness

Decision-making Questions

- What are the (health) benefits?
- What are the harms?
- Will there be net benefit in the real-world?
- What is the incremental benefit?
- What is the feasibility?
- What is the cost-effectiveness and cost?

- Other issues: preferences, convenience, coverage/reimbursement etc.

EB(D)M ≠ RCT

- USPSTF recommendations in absence of RCT data
 - cervical cancer screening
 - PKU screening
- EPC report on obesity Rx:
 - surgery more effective for $BMI > 40$

AHRQ website

Comparative Effectiveness

■ What?

Clinical interventions: test, device, drug, dietary supplement, biologic, surgical procedure, counseling/behavioral intervention etc.

Methods (how?)

- Design:
 - a) Experimental: RCT (head-to-head, effectiveness), cluster randomized trials
 - b) Observational: cohort, case-control
 - c) Modeling
 - d) Systematic reviews, meta-analyses
- Analytic techniques: approaches to minimize bias and confounding (improve internal validity)



Comparative Effectiveness Research at AHRQ

- Created in 2005, authorized by Section 1013 of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003
- AHRQ shall conduct and support research on:
 - “the outcomes, comparative clinical effectiveness, and appropriateness of health care items and services (including prescription drugs)”
- Goal: to provide patients, clinicians and policy makers with reliable, evidence-based healthcare information




Effective Health Care Program

- To improve the quality, effectiveness, and efficiency of health care delivered through Medicare, Medicaid, and S-CHIP programs
 - Focus is on what is known **now**: ensuring programs benefit from **past** investments in research and what research **gaps** are critical to fill
 - Focus is on ***clinical effectiveness***

Conceptual Framework

**Stakeholder Input
& Involvement**



Output



Effective Health Care

Number 12

Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis

Executive Summary

Background

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. The clinical complications of osteoporosis include fractures, disability, and chronic pain. Approximately 44 million people in the United States are affected by osteoporosis or low bone density. It is

Effective Health Care Program

The Effective Health Care Program was initiated in 2005 to provide valid evidence about the comparative effectiveness of different medical interventions. The object is to help consumers, health care providers, and others in making informed choices among treatment alternatives. Through its Comparative Effectiveness Reviews, the program supports systematic



Effective Health Care

Number 8

Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes

Executive Summary

Background

Type 2 diabetes is characterized by insulin resistance accompanied by progressive deficiency in insulin secretion. Type 2 diabetes is an increasingly common disease that is closely associated with obesity. In 2005, the prevalence of Americans with diagnosed type 2 diabetes was 2.4 percent for adults aged 20-39 years, 10 percent for adults aged 40-59 years, and 21 percent for adults aged 60 years or over. From 1980 through 2004, the number of Americans diagnosed with diabetes more than doubled, from 5.8 million to 14.7 million. Observational studies and clinical trials show that improved glycemic control reduces microvascular complications (e.g., complications involving the eyes, kidneys, or nerves) and may reduce macrovascular complications (e.g., heart attack); however, the effects of specific oral diabetes medications on these outcomes are less certain.

As new classes of medications have become available for the treatment of diabetes, clinicians and patients have faced a bewildering array of oral medications with different mechanisms of action. The first oral diabetes medications were sulfonylureas, which were introduced into the market in 1955. The second-generation sulfonylureas, which are used today, were

Effective Health Care Program
The Effective Health Care Program was initiated in 2005 to provide valid evidence about the comparative effectiveness of different medical interventions. The object is to help consumers, health care providers, and others in making informed choices among treatment alternatives. Through its Comparative Effectiveness Reviews, the program supports systematic appraisals of existing scientific evidence regarding treatments for high-priority health conditions. It also promotes and generates new scientific evidence by identifying gaps in existing scientific evidence and supporting new research. The program puts special emphasis on translating findings into a variety of useful formats for different stakeholders, including consumers.

The full report and this summary are available at www.effectivehealthcare.ahrq.gov/reports/final.cfm



AHRQ
Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Effective Health Care

Educating Clinicians

- Concise
- Actionable
- Paired with consumer guides
- Convey level of uncertainty/certainty of findings

Effective Health Care

Clinician's Guide

Confidence Scale

The confidence ratings in this guide are derived from a systematic review of the literature. The level of confidence is based on the:

- High: The evidence comes from well-conducted studies.
- Medium: The evidence comes from studies with some methodological problems.
- Low: The evidence comes from studies with major methodological problems.
- Very Low: There is very little evidence, or existing studies are flawed.

Off-Label Use of ATYPICAL ANTIPSYCHOTIC DRUGS

A Summary for Clinicians and Policymakers

ATYPICAL ANTIPSYCHOTICS

Atypical antipsychotics are used primarily for schizophrenia and bipolar mania. They are also prescribed "off-label" for symptoms like agitation, anxiety, psychotic episodes, and obsessive behaviors. These drugs can cause serious side effects. Evaluating research about how well atypical antipsychotics work for off-label conditions can help you weigh the benefits and risks of these drugs. The chart on the back page gives information on dosage and price.

ATYPICAL ANTIPSYCHOTICS

Atypical antipsychotics are a newer class of antipsychotic drugs. Compared with the older "typical" antipsychotic drugs, such as haloperidol (Haldol[®]) and chlorpromazine ("Thorazine"), atypicals are thought to cause fewer serious or long-term side effects.

The typical antipsychotic drugs reviewed are:

- Aripiprazole (Abilify[®])
- Clorazepate (Zyprexa[®])
- Quetiapine (Seroquel[®])
- Risperidone (Risperidol[®])
- Ziprasidone (Geodon[®])

OFF-LABEL USE

"Off-label" refers to using a drug for conditions not listed on the Food and Drug Administration (FDA) label of approved uses. Drugs are commonly prescribed off-label when approved drugs cannot be used or do not work. Off-label uses may be supported by clinical evidence. This guide covers the off-label use of atypicals for these six conditions:

- Dementia-related behavioral problems
- Depression
- Obsessive-compulsive disorder (OCD)
- Post-traumatic stress disorder (PTSD)
- Personality disorders
- Tourette's syndrome in children and adolescents

SOURCE

This source material for this summary is a systematic review of over 100 research publications. The review, *Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics* (2007), was prepared by the Southern California RAND Evidence-based Practice Center. The Agency for Healthcare Research and Quality (AHRQ) funded the systematic review and this guide. The guide was developed using feedback from clinicians and policymakers who reviewed preliminary drafts.

CHOOSING NON-OPIOID ANALGESICS FOR Osteoarthritis

This guide summarizes clinical evidence on the effectiveness and safety of non-opioid analgesics for osteoarthritis. It covers most available over-the-counter (OTC) medications and prescription non-steroidal anti-inflammatory drugs (NSAIDs). The reviewed drugs are listed on the back page. This guide does not address non-pharmacologic therapies such as diet, exercise, acupuncture, or surgical interventions.

Clinical Issue

Osteoarthritis is a chronic condition associated with joint pain that can assist in maintaining mobility and among the available prescription and over-the-counter treatment of benefits, risks, and cost.

atments for osteoarthritis are:

- Coxib.
- Salicin, topical salicylates, and topical NSAIDs.

pain but is inferior to NSAIDs for reducing aminophen has fewer systemic side effects than

- •

equally well for pain reduction.

- •

I bleeding. The risk increases with higher doses years old have the highest risk.

- •

and, high dose diclofenac increase the risk of en does not increase the risk of myocardial

- •

ic osteoarthritic pain, but about half of the local burning sensations. The burning

- •

on osteoarthritis pain.

 **AHRQ**
Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

JULY 2007

Challenge of Genomics

- Large volume of gene-based information
- Relatively quick and easy to generate
- Little information on outcomes (EGAPP)
- Paucity of information on added value
- Concern of rapid and inappropriate dissemination
- Limited skills and training of providers to tackle genomics, especially primary care
- Healthcare system is ill-equipped

Future Steps

- Randomized effectiveness trials when feasible
- Improve observational study design and analysis methods to minimize bias and confounding (improve internal validity)
- Invest in electronic infrastructure to enhance clinical data collected for studies
 - example: distributed research network
- Consistency and transparency in using comparative effectiveness to make decisions
- Build public-private partnerships (CED?)
- Invest in clinical decision support tools



Thank you!

Effective Health Care:
<http://effectivehealthcare.ahrq.gov>